This post first appeared on SEC Filings – Market Exclusive

Dyadic International, Inc. (OTCMKTS:DYAI) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement

On May 7, 2019, Dyadic International, Inc. (“Dyadic” or the “Company”) entered into a research and commercialization collaboration with Serum Institute of India Pvt., Ltd (“Serum”).
Under the terms of this collaboration, Serum anticipates applying Dyadic’s C1 technology to express up to twelve (12) antibodies and vaccines and will undertake commercially best efforts to fully develop and commercialize the proteins expressed from Dyadic’s C1 technology. Dyadic has agreed to grant Serum the option to obtain an exclusive commercial sub-license for each of the twelve (12) proteins in return for certain research funding, milestone payments and royalties for 15 years from the date of the first commercial sale.
The foregoing description of the research and commercialization collaboration is qualified in its entirety by reference to the complete terms and conditions of the agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.
Item 8.01 Other Events
On May 8, 2019, Dyadic issued a press release announcing the entry into a research and commercialization collaboration in Item 1.01 on this Current Report on Form 8-K. A copy of this press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
DYADIC INTERNATIONAL INC Exhibit
EX-10.1 2 a101serumresearchandcommer.htm EXHIBIT 10.1 Exhibit Exhibit 10.1Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.Research and Commercialization Work PlanEXECUTION COPYThe Development and Commercialization of Recombinant Vaccines and Therapeutic Proteins Using Dyadic’s C1 Fungal Expression System as the Commercial Production Platform 1.    Introduction•Serum Institute of India Private Limited,…
To view the full exhibit click here

About Dyadic International, Inc. (OTCMKTS:DYAI)

Dyadic International, Inc. (Dyadic) is a holding company. The Company is a global biotechnology company with operations in the United States and the Netherlands. Dyadic uses its technologies to conduct research, development and commercial activities for the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceuticals and industrial enzymes industries. Its activities relating to selling enzymes focuses on utilizing its fungal strains and associated technologies. In particular, Dyadic uses its Trichoderma and C1 (Myceliopthora thermophila) fungal strains in the production of its industrial enzymes. Dyadic manufactures, purchases, and sells liquid and dry enzyme products to global customers for use within the animal feed, pulp and paper, starch and alcohol, food and brewing, textiles and biofuels industries. It is focused on biofuels and bio-based chemicals, biopharmaceuticals and industrial products.

The post Dyadic International, Inc. (OTCMKTS:DYAI) Files An 8-K Entry into a Material Definitive Agreement appeared first on Market Exclusive.

--
Copyright in text and images in this article belong to the original source.

This post first appeared on SEC Filings – Market Exclusive